Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Partnership
Biomay Cooperates with BioNTech to Supply DNA Template for COVID-19 mRNA Vaccine
Details : Biomay is one of the manufacturers supplying BioNTech with the DNA template for the in-vitro transcription of their mRNA active ingredient. The manufacturing agreement was initiated during the clinical development phase of the Comirnaty vaccine in Q1/202...
Product Name : Comirnaty
Product Type : Vaccine
Upfront Cash : Undisclosed
May 17, 2021
Lead Product(s) : Tozinameran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : BM32
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 31, 2015
Lead Product(s) : BM32
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BM32
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study of Grass Pollen Allergy Vaccine BM32
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 27, 2012
Lead Product(s) : BM32
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BM32
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 03, 2011
Lead Product(s) : BM32
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BM32
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Medical University of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 10, 2011
Lead Product(s) : BM32
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Medical University of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
